We evaluated the clinicopathologic and molecular characteristics of mostly incidentally detected, small, papillary renal neoplasms with reverse polarity (PRNRP). The cohort comprised 50 PRNRP from 46 patients, divided into 2 groups. The clinically undetected (<5 mm) neoplasms (n = 34; 68%) had a median size of 1.1 mm (range 0.2-4.3 mm; mean 1.4 mm), and the clinically detected (≥5 mm) neoplasms (n = 16; 32%) which had a median size of 13 mm (range 9-30 mm; mean 16 mm). Neoplasms were positive for GATA3 (n = 47; 100%) and L1CAM (n = 34/38; 89%) and were negative for vimentin (n = 0/44; 0%) and, to a lesser extent, AMACR [(n = 12/46; 26%; weak = 9, weak/moderate = 3)]. KRAS mutations were found in 44% (n = 15/34) of the clinically undetected PRNRP and 88% of the clinically detected PRNRP (n = 14/16). The two clinically detected PRNRP with wild-type KRAS gene were markedly cystic and contained microscopic intracystic tumors. In the clinically undetected PRNRP, the detected KRAS mutations rate was higher in those measuring ≥1 mm vs <1 mm [n = 14/19 (74%) vs n = 1/15 (7%)]. Overall, the KRAS mutations were present in exon 2-codon 12: c.35 G > T (n = 21), c.34 G > T (n = 3), c.35 G > A (n = 2), c.34 G > C (n = 2) resulting in p.Gly12Val, p. Gly12Asp, p.Gly12Cys and p.Gly12Arg, respectively. One PRNRP had a G12A/V/D complex mutation. Twenty-six PRNRP were concurrently present with other tumors of different histologic subtypes in the ipsilateral kidney; molecular testing of 8 of the latter showed wild-type KRAS gene despite the presence of KRAS mutations in 5 concurrent PRNRP. On follow up, no adverse pathologic events were seen (range 1-160 months; mean 44 months). In conclusion, the presence of KRAS mutations in small, clinically undetected PRNRP provides a unique finding to this entity and supports its being an early event in the development of these neoplasms.

Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada

Department of Pathology and Laboratory Medicine Cumming School of Medicine University of Calgary Calgary AB Canada

Department of Pathology and Laboratory Medicine Henry Ford Hospital Detroit MI USA

Department of Pathology and Laboratory Medicine School of Medicine Indiana University Indianapolis IN USA

Department of Pathology Charles University Prague Faculty of Medicine and University Hospital in Plzen Plzen Czech Republic

Department of Pathology El Camino Hospital Mountain View CA USA

Department of Pathology Emory University School of Medicine Atlanta GA USA

Department of Pathology Regional Laboratory and Blood Bank Eastern Province Dammam Saudi Arabia

Department of Pathology Wayne State University Detroit Medical Center Detroit MI USA

Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA

Section of Pathological Anatomy School of Medicine United Hospitals Marche Polytechnic University Ancona Italy

Women's and Perinatal Pathology Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA

Zobrazit více v PubMed

Al-Obaidy, K. I. et al. Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study. Am. J. Surg. Pathol. 43, 1099–1111 (2019). DOI

Al-Obaidy, K. I. et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod. Pathol 33, 1157–1164 (2020). DOI

Trpkov, K. et al. New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 34, 1392–1424 (2021). DOI

Kunju, L. P., Wojno, K., Wolf, J. S. Jr, Cheng, L. & Shah, R. B. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum. Pathol 39, 96–101 (2008). DOI

Saleeb, R. M. et al. Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis. Am. J. Surg. Pathol. 41, 1618–1629 (2017). DOI

Chang, H. Y. et al. Clinicopathological and molecular characterisation of papillary renal neoplasm with reverse polarity and its renal papillary adenoma analogue. Histopathology 78, 1019–1031 (2021). DOI

Kim, S. S. et al. Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma. Mod Pathol 33, 690–699 (2020). DOI

Kiyozawa, D. et al. Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity. Hum Pathol 112, 48–58 (2021). DOI

Lee, H. J. et al. Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with KRAS and PIK3CA mutations. Diagn. Pathol 15, 123 (2020). DOI

Wei, S. et al. Papillary renal neoplasm with reverse polarity is often cystic: report of 7 cases and review of 93 cases in the literature. Am. J. Surg. Pathol. https://doi.org/10.1097/PAS.0000000000001773 (2021). Online ahead of print.

Zhou, L. et al. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 7 cases. Int. J. Surg. Pathol. 28, 728–734 (2020). DOI

Tong, K. et al. Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei. Histopathology 76, 1070–1083 (2020). DOI

Brunelli, M., Eble, J. N., Zhang, S., Martignoni, G. & Cheng, L. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol 16, 1053–1059 (2003). DOI

Calio, A., Warfel, K. A. & Eble, J. N. Papillary adenomas and other small epithelial tumors in the kidney: an autopsy study. Am. J. Surg. Pathol. 43, 277–287 (2019). DOI

Al-Obaidy, K. I. et al. Recurrent KRAS mutation is an early event in the development of papillary renal neoplasm with reverse polarity (abstract 1865). Mod Pathol 33, 1002–1163 (2020). DOI

Mantilla, J. G., Antic, T. & Tretiakova, M. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics. Hum Pathol 66, 152–158 (2017). DOI

Priemer, D. S., Vortmeyer, A. O., Zhang, S., Chang, H. Y., Curless, K. L. & Cheng, L. Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation. Hum Pathol 89, 33–39 (2019). DOI

Thoenes, W., Storkel, S. & Rumpelt, H. J. Human chromophobe cell renal carcinoma. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 48, 207–217 (1985). DOI

Pivovarcikova, K. et al. Renal cell carcinomas with tubulopapillary architecture and oncocytic cells: Molecular analysis of 39 difficult tumors to classify. Ann. Diagn. Pathol. 52, 151734 (2021). DOI

Koski, T. A. et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer 48, 544–551 (2009). DOI

Pivovarcikova, K. et al. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases. Cesk Patol 55, 244–249 (2019). PubMed

Chen, N. et al. Gains of chromosomes 7 and 17 in tubulocystic carcinoma of kidney: two cases with fluorescence in situ hybridisation analysis. J. Clin. Pathol. 67, 1006–1009 (2014). DOI

Sarungbam, J. et al. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile. Mod. Pathol 32, 701–709 (2019). DOI

Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists